secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001171843-22-006960
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports Q3 net loss $9.8M; tuspetinib completes dose escalation with CRs in FLT3+ AML
--------------------------------------------------------------------------------

- Net loss $9.8M ($0.11/share) vs $11.3M ($0.13) in Q3 2021; cash $55.4M funds operations into Q1 2024.
- Tuspetinib (HM43239) completes Phase 1/2 dose escalation; 120mg selected for single-agent expansion, 80mg with venetoclax.
- FLT3-mutant patients with prior FLT3 inhibitor failure achieved complete remissions; responses also in FLT3 wildtype with TP53/NRAS.
- Luxeptinib G3 formulation shows ~18-fold bioavailability improvement; continuous dosing of 50mg Q12h to start shortly.
- USAN Council adopted generic name 'tuspetinib'; Aptose will use for all future references.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/f8k_110122.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-006960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer